Category: Side Effect: Cardiovascular (heart attack, stroke, heart failure, PE, DVT)
-
Eli Lilly Attempts to Distance Olumiant From the Ominous JAK Inhibitors Drug Class Safety Issues Flagged by FDA
Xeljanz, Rinvoq, and Olumiant Are the Three Janus Kinase (JAK) Inhibitors Getting "Black-Box" Warnings Revisions, Soon (Posted by Tom Lamb at Drug Injury Watch) In September 2021 the FDA announced it was requiring revisions to…
-
Xeljanz Risks of Cardiovascular Events, as Well as Cancers, Cause More Xeljanz Use Limitations
October 2021 UK’s MHRA Xeljanz Action Follows September 2021 FDA Xeljanz Drug Safety Communication Update (Posted by Tom Lamb at Drug Injury Watch) On September 1, 2021, we posted this article, “Xeljanz: FDA Warnings Updated:…
-
Xeljanz: FDA Warnings Updated: There are Higher Rates of Blood Clots and Deaths for Both Doses of Xeljanz, Now
JAK Inhibitors Xeljanz, Olumiant, and Rinvoq Get Drug Label Changes and Drug Use Limitations in September 2021 (Posted by Tom Lamb at Drug Injury Watch) On September 1, 2021, the FDA released this alerting news…
-
Tasigna Lawsuits Federal Court MDL Order Issued in August 2021 After July 2021 JPML Hearing
Consolidation of Tasigna Drug Injury Cases Involving Atherosclerosis-related Diseases and Medical Conditions (Posted by Tom Lamb at Drug Injury Watch) On August 12, 2021, the United States Judicial Panel on Multidistrict Litigation (JPML) created a…
-
Possible FDA Advisory Committee Meeting for Xeljanz, Rinvoq, and Other Janus Kinase (JAK) Inhibitors
Outside Experts Could Review All JAK Inhibitors Risk/Benefit Profiles as Regards Several Requested New Indications (Posted by Tom Lamb at Drug Injury Watch) A few months ago we wrote about a possible FDA Advisory Committee…